Keywords: Probes & Targets, Molecular Imaging, glioma
Motivation: Advanced theranostic nanoagents for imaging-guided photothermal therapy (PTT) can enhance therapeutic efficacy and enable precise treatment of glioma.
Goal(s): To develop a tumor cell membrane (CM)-camouflaged theranostic nanoagent , enabling photothermal imaging (PI) and MR dual-modal imaging -guided glioblastoma therapy.
Approach: MPDA was firstly chelated with ferric ion (Fe3+), and then loaded with ICG via electrostatic/hydrophobic interactions. Finally, the MPDA-Fe3+-ICG NPs was coated with C6 glioma CM.
Results: NPs exhibited superior photothermal and MR imaging performance, its T1 relativity (r1 = 25.6 mM−1S−1) is approximately 6 folders of the commercial Gd-DTPA. Endowing PI/MRI dual-modal imaging -guided remarkable therapeutic efficiency and minimal side effects.
Impact: This study illustrates that the highly integrated and biocompatible MPDA-based NPs can serve as a versatile nanoplatform by loading different imaging molecules and drugs for multi-modal imaging and cancer combination therapy.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords